Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels

Journal of Cataract and Refractive Surgery
Frank A Bucci, L David Waterbury

Abstract

To compare aqueous drug concentrations and prostaglandin E(2) (PGE(2)) levels in patients treated with ketorolac 0.4% and bromfenac 0.09% at trough dosing. Private practice, Wilkes-Barre, Pennsylvania, USA. This single-center randomized investigator-masked clinical study comprised 56 patients having cataract surgery. Patients received 1 drop of ketorolac 0.4% or bromfenac 0.09% 6 hours and 12 hours preoperatively consistent with on-label dosing schedules. Aqueous humor was collected at the start of surgery and analyzed for concentrations of ketorolac and bromfenac using a reverse-phase high-performance liquid chromatography-mass spectroscopy system and for PGE(2) levels by competitive enzyme immunoassay. The mean aqueous PGE(2) level was 204.2 pg/mL +/- 95.5 (SD) in patients treated with ketorolac 0.4% and 263.7 +/- 90.0 pg/mL in patients treated with bromfenac 0.09%, (P = .020). The mean aqueous concentration of ketorolac and bromfenac at trough dosing was 130.5 +/- 37.8 ng/mL and 6.2 +/- 3.1 ng/mL, respectively (P = .004). Higher aqueous levels and greater PGE(2) inhibition were observed in cataract surgery patients treated with ketorolac 0.4% than in patients treated with bromfenac 0.09% at trough dosing. These findings sugg...Continue Reading

Associated Clinical Trials

References

May 1, 1996·The British Journal of Ophthalmology·P Koay
Mar 21, 2000·Current Opinion in Ophthalmology·A Z McColgin, J S Heier
Mar 21, 2000·Current Opinion in Ophthalmology·L Rossetti, A Autelitano
May 1, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Timothy D Warner, Jane A Mitchell
Aug 18, 2004·Journal of Cataract and Refractive Surgery·Kerry D SolomonUNKNOWN Ketorolac Reformulation Study Groups 1 and 2
Feb 11, 2005·Current Medical Research and Opinion·Marianne O Price, Francis W Price
Dec 24, 2005·Expert Opinion on Pharmacotherapy·Henry D Perry, Eric D Donnenfeld
Aug 17, 2006·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Helga P SandovalKerry D Solomon
Aug 26, 2006·Journal of Cataract and Refractive Surgery·Eric D DonnenfeldTimothy Chou
Apr 21, 2007·Ophthalmology·Eric D DonnenfeldUNKNOWN Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group

❮ Previous
Next ❯

Citations

Mar 1, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·L David WaterburyDavid A Hollander
Sep 9, 2009·Expert Opinion on Pharmacotherapy·J Jones, P Francis
Jun 24, 2009·Journal of Cataract and Refractive Surgery·Johnny Gayton
Sep 30, 2010·Journal of Pediatric Ophthalmology and Strabismus·Carmen GiannantonioCostantino Romagnoli
Jun 13, 2015·Asia-Pacific Journal of Ophthalmology·Hiroshi FujishimaDogru Murat
Dec 10, 2009·Current Opinion in Ophthalmology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.